Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Effectiveness of Abstral for Breakthrough Cancer Pain
NCT00263575Phase 3Completed
- Sponsor
- Kyowa Kirin
- Start
- Dec 2005
- Primary completion
- Dec 2008
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fentanyl in breakthrough pain, sponsored by Kyowa Kirin. Primary endpoint: Evaluate the Long-term Safety and Effectiveness of EN3267 at 12 months. Started Dec 2005; status: completed.
02
Drugs
fentanyl
03
Conditions
breakthrough pain
Beyond the preview
Go deeper on NCT00263575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00263575.